Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma
暂无分享,去创建一个
Scott E. Smith | J. Connors | K. Savage | A. Younes | S. Ansell | A. Engert | J. Rosenblatt | D. Huebner | E. Sievers | E. K. Larsen | Robert Chen